GenSight Biologics S.A.
PAR: SIGHT.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurence Rodriguez
- Employees
- 16
- Headquarters
- Paris, France
- IPO year
- 2016
- Market cap
- €13.1M
- Website
- https://www.gensight-biologics.com
Loading SIGHT…
Loading profile data…Frequently asked questions about SIGHT
What does GenSight Biologics S.A. (SIGHT.PA) do?
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technolog...
Where does SIGHT.PA trade?
GenSight Biologics S.A. (SIGHT.PA) trades on the Euronext Paris.
What sector is SIGHT.PA in?
GenSight Biologics S.A. (SIGHT.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GenSight Biologics S.A.?
Laurence Rodriguez is the chief executive officer of GenSight Biologics S.A. (SIGHT.PA).
Where is GenSight Biologics S.A. headquartered?
GenSight Biologics S.A. is headquartered in France.
Does SIGHT.PA pay a dividend?
GenSight Biologics S.A. (SIGHT.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SIGHT.PA go public?
GenSight Biologics S.A. (SIGHT.PA) completed its initial public offering in 2016.